Veltassa (Patiromer Calcium Sorbitex) Patent Expiration, LOE Window & CMS Spending
Veltassa (Patiromer Calcium Sorbitex) by Vifor: FDA Orange Book core substance LOE 2030-05-29 (last listed 2033-10-08), 0 AB generics, $192.3M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Vifor |
| FDA Application & Pathway | N205739 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-05-29 |
| Last Listed Patent or Exclusivity Date | 2033-10-08 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $192.3M |
| 2024 Medicare Part D Spend | $175.1M |
| 2024 Medicaid Spend | $17.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |